Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review

Bibliography

• Yatham LN, Kennedy SH, Schaffer A, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225-55
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The world federation of societies of biological psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11:81-109
   PubMed Web of Science ®Google Scholar
• Cruz N, Vieta E. Antidepressants in acute bipolar depression: an inconclusive meta-analysis. J Clin Psychiatry 2011;72:415-16
   PubMedGoogle Scholar
• Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2012;262(Suppl 1):1-48
   PubMed Web of Science ®Google Scholar
• Srivastava S, Ketter TA. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clin Ther 2011;33(12):B40-8
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord 2011;13(4):pii: PCC.10r01097- doi: 10.4088/PCC.10r01097
   Google Scholar
• Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009;166:164-72
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000;61:804-8
   PubMed Web of Science ®Google Scholar
• Rossi A, Barraco A, Donda P. Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry 2004;3:2
   PubMedGoogle Scholar
• Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat 2009;5:369-83
   PubMed Web of Science ®Google Scholar
• Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother 2011;12(17):2751-8
   PubMed Web of Science ®Google Scholar
• Bobo WV, Epstein RA Jr, Shelton RC. Acute bipolar depression: a review of the use of olanzapine/fluoxetine. Clin Med Insights Ther 2010;2:825-40. doi: 10.4137/CMT.S1945
   Google Scholar
• Deeks ED, Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. Drugs 2008;68(8):1115-37
   PubMedGoogle Scholar
• Brunswick DJ, Amsterdam JD, Fawcett J, et al. Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy. J Clin Psychopharmacol 2001;21:616-18
   PubMedGoogle Scholar
• Wernicke JF. Safety and side effect profile of fluoxetine. Expert Opin Drug Saf 2004;3:495-504
   PubMedGoogle Scholar
• Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4(4):313-22
   PubMed Web of Science ®Google Scholar
• Simpson SG, DePaulo JR. Fluoxetine treatment of bipolar II depression. J Clin Psychopharmacol 1991;11(1):52-4
   PubMedGoogle Scholar
• Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998;18(6):435-40
   PubMedGoogle Scholar
• Amsterdam JD, Shults J, Brunswick DJ, Hundert M. Short-term fluoxetine monotherapy for bipolar Type II or bipolar NOS major depression - low manic switch rate. Bipolar Disord 2004;6(1):75-81
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar Type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005;20(5):257-64
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar Type I and Type II major depression–lack of manic induction. J Affect Disord 2005;87(1):121-30
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol 2010;30(3):306-11
   PubMedGoogle Scholar
• Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010;167(7):792-800
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Luo L, Shults J. Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder. Br J Psychiatry 2012; Epub ahead of print
   PubMedGoogle Scholar
• Malhi GS, Adams D, Lampe L, et al. Northern Sydney Central Coast Mental Health Drug & Alcohol; NSW Health Clinical Redesign Program; CADE Clinic, University of Sydney. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009(439):27-46
   PubMedGoogle Scholar
• Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord 2012;14(Suppl 2):37-50
   PubMed Web of Science ®Google Scholar
• Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010;121(6):404-14; Epub 2009 Dec 2
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12
   PubMed Web of Science ®Google Scholar
• Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006;96:95-9
   PubMedGoogle Scholar
• Fonseca M, Soares JC, Hatch JP, et al. An open trial of adjunctive escitalopram in bipolar depression. J Clin Psychiatry 2006;67:81-6
   PubMed Web of Science ®Google Scholar
• Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol 2012;32:487-91
   PubMed Web of Science ®Google Scholar
• Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents 2011;25:109-14
   PubMed Web of Science ®Google Scholar
• Sepede G, Corbo M, Fiori F, Martinotti G. Reboxetine in clinical practice: a review. Clin Ther 2012;163:e255-62
   Google Scholar
• Farina B, Della Marca G, Mennuni G, et al. The effects of reboxetine on human sleep architecture in depression: preliminary results. J Affect Disord 2002;71:273-5
   PubMed Web of Science ®Google Scholar
• Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001;62(4):249-55
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology 2010;35(13):2545-52
   PubMedGoogle Scholar
• Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008;23:417-24
   PubMed Web of Science ®Google Scholar
• Sepede G, De Berardis D, Campanella D, et al. Impaired sustained attention in euthymic bipolar disorder patients and non-affected relatives: an fMRI study. Bipolar Disord 2012;14:764-79
   PubMed Web of Science ®Google Scholar
• Mandelli L, Mazza M, Di Nicola M, et al. Role of substance abuse comorbidity and personality on the outcome of depression in bipolar disorder: harm avoidance influences medium-term treatment outcome. Psychopathology 2012;45:174-8
   PubMed Web of Science ®Google Scholar
• Mandelli L, Mazza M, Martinotti G, et al. Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients. J Affect Disord 2009;119:205-9
   PubMed Web of Science ®Google Scholar
• Feighner JP, Boyer WF, Merideth CH, Hendrickson GG. A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol 1989;4(2):127-34
   PubMedGoogle Scholar
• Emslie GJ, Rush AJ, Weinbert WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-7
   PubMed Web of Science ®Google Scholar
• Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992;49:139-47
   PubMed Web of Science ®Google Scholar
• Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993;3(2):143-52
   PubMedGoogle Scholar